Axcan Pharma Inc. company develops and sells drugs mainly to treat gastrointestinal ailments. Its Urso line treats chronic liver disease, while two of its products (Canasa and Salofalk) offer relief for inflammatory bowel diseases. Axcan's Ultrase and Viokase are digestive aids for patients with exocrine pancreatic insufficiency, a condition associated with cystic fibrosis. The firm also owns the global rights to Photofrin, a photodynamic drug developed by QLT with applications for esophageal, gastric, and lung cancers. Other products include ulcer and diarrhea treatments, as well as chewable multivitamins. Axcan was acquired by TPG Capital for $1.3 billion in early 2008.

Paddock Laboratories, Inc. company was founded in 1977 by Chairman Bruce Paddock. Paddock Laboratories, Inc. company develops and manufactures bioequivalent generic pharmaceuticals and OTC specialty products. Paddock's product line includes suppositories, diabetes treatments, topical powders, enemas, injectables, and dermatological offerings, as well as compounding bases and charcoal products. Its manufacturing facilities are located in Minneapolis, Minnesota. In addition to the US market, some of Paddock's products are sold in Europe and the Asia/Pacific region through distributors.

Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

Novogen Limited company was founded in 1994 and is headquartered in North Ryde, Australia. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. In February, 2009, the Company announced that it focuses its activities on its oncology program. The Company operates subsidiary companies in 3 geographical areas: Australia, North America and Europe. The subsidiaries are involved in the selling and marketing of Novogen's consumer healthcare products. The Company’s product range includes Phenoxodiol, Triphendiol, NV-128, and GLYC-101. The Company’s subsidiaries include Novogen Laboratories Pty Ltd, Norvogen Pty Ltd, Glycotex, Inc. and Novogen BV.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

Caprius, Inc. company owns a majority interest in MCM Environmental Technologies, which provides systems for disposal of medical waste. Its SteriMed system can crush, grind, shred, and mix all types of medical waste, including metal sharps and needles, plastic tubing and IV bags, and glass items. Once this process is complete, MCM's Steri-Cid chemical process disinfects the waste, which can then be discarded as regular waste at as little as 10% of the original volume. MCM manufactures the SteriMed system in Israel; the company distributes parts and supplies from facilities in Israel. Officers and directors, led by Austin W. Marxe and David M. Greenhouse hold about 22% of Caprius.

Actavis U.S. is the US manufacturing and marketing unit of global generics firm Actavis. The company makes a wide variety of generic equivalents of both prescription and OTC drugs, in a number of forms, including liquids, tablets, creams, and suppositories. Among other consumer and specialty drugs, it makes acetaminophen, ibuprofen, and generic Rogaine. It has also launched generic versions of Pfizer's diabetes drug Glucotrol XL and GlaxoSmithKlein's Coreg tables for hypertension and myocardial infarction. Actavis U.S. has manufacturing facilities in Maryland, New Jersey, and North Carolina, from which it ships its own products and provides contract manufacturing services to third parties.

De Novo Pharmaceuticals, Ltd. was incorporated in 1999 and is based in Cambridge, the United Kingdom. De Novo Pharmaceuticals, Ltd., a drug discovery company, provides computational drug design services. It focuses on small molecule therapeutics. The company provides services to drug discovery customers seeking progress from validated target to novel hits; and to medicinal chemistry groups interested in focused chemical libraries. It offers SkelGen, a chemical structure-generation platform and a suite of software tools for the analysis of structural information on a protein target and the de novo design of molecules to bind into its site, as well as for the hit and lead discovery to the pharmaceutical industry. The company offers its SkelGen for scaffold hopping, virtual high-throughput screening, focused library design, intelligent fragment linking, and low affinity fragment-based design applications. It also provides drug discovery partnerships, such as structure-based drug design, ligand-based drug design, and fragment-based drug design services, as well as focused libraries for medicinal chemistry seeking the design of focused libraries against classes of targets. In addition, the company involves in applying its SkelGen silico drug design platform to design compounds for various targets within the diabetes field.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.